GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » BioAdaptives Inc (OTCPK:BDPT) » Definitions » EV-to-EBIT

BioAdaptives (BioAdaptives) EV-to-EBIT : -1.38 (As of May. 12, 2024)


View and export this data going back to 2014. Start your Free Trial

What is BioAdaptives EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, BioAdaptives's Enterprise Value is $0.76 Mil. BioAdaptives's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.55 Mil. Therefore, BioAdaptives's EV-to-EBIT for today is -1.38.

The historical rank and industry rank for BioAdaptives's EV-to-EBIT or its related term are showing as below:

BDPT' s EV-to-EBIT Range Over the Past 10 Years
Min: -37.43   Med: -7.42   Max: 0.05
Current: -1.38

During the past 9 years, the highest EV-to-EBIT of BioAdaptives was 0.05. The lowest was -37.43. And the median was -7.42.

BDPT's EV-to-EBIT is ranked worse than
100% of 1471 companies
in the Consumer Packaged Goods industry
Industry Median: 14.1 vs BDPT: -1.38

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. BioAdaptives's Enterprise Value for the quarter that ended in Dec. 2023 was $0.72 Mil. BioAdaptives's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.55 Mil. BioAdaptives's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -76.58%.


BioAdaptives EV-to-EBIT Historical Data

The historical data trend for BioAdaptives's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioAdaptives EV-to-EBIT Chart

BioAdaptives Annual Data
Trend Dec13 Dec14 Dec15 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only -73.94 -1.59 -1.11 -0.86 -1.30

BioAdaptives Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.86 -1.23 -2.16 -7.90 -1.30

Competitive Comparison of BioAdaptives's EV-to-EBIT

For the Packaged Foods subindustry, BioAdaptives's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioAdaptives's EV-to-EBIT Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, BioAdaptives's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where BioAdaptives's EV-to-EBIT falls into.



BioAdaptives EV-to-EBIT Calculation

BioAdaptives's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=0.755/-0.549
=-1.38

BioAdaptives's current Enterprise Value is $0.76 Mil.
BioAdaptives's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.55 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioAdaptives  (OTCPK:BDPT) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

BioAdaptives's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=-0.549/0.71688
=-76.58 %

BioAdaptives's Enterprise Value for the quarter that ended in Dec. 2023 was $0.72 Mil.
BioAdaptives's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.55 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioAdaptives EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of BioAdaptives's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


BioAdaptives (BioAdaptives) Business Description

Traded in Other Exchanges
N/A
Address
2620 Regatta Drive, Suite 102, Las Vegas, NV, USA, 89128
BioAdaptives Inc is engaged in investigating, marketing and distributing natural plant- and algal-based products and medical devices that improve health and wellness for humans and animals, with an emphasis on pain relief, anti-viral function, and anti-aging properties. Its products include dietary supplements using natural ingredients and proprietary methods of optimizing the availability of nutrients in foods and beverages. The human products are designed to aid memory, cognition and focus; assist in sleep and fatigue reduction; provide pain relief and healing; and improve overall emotional and physical wellness. Its product lines include PluriPain, PrimiLungs, SleepEZ, MindNMemory, Cell Rejuven and ProteinNMore.
Executives
Richard Chiang other: Previous Officer and Director 460 BRANNAN STREET SUITE 78064, SAN FRANCISCO CA 94107
Barry Epling director 2251 NORTH RAMPART BLVD., #182, LAS VEGAS NV 89128
Ferris Holding Inc. 10 percent owner 2251 NORTH RAMPART BLVD., #182, LAS VEGAS NV 89128
Gerald Epling director, officer: Pres, CEO, Secretary, CFO 2251 NORTH RAMPART BLVD., #182, LAS VEGAS NV 89128

BioAdaptives (BioAdaptives) Headlines